ASC
23.5.2022 09:11:12 CEST | Business Wire | Press release
The 29th HPC Connection Workshop (HPCC) will be held online at 2pm (CEST) on May 30, 2022, at ISC22 with the theme "The Latest Convergence of AI & HPC." World renowned experts and industry leaders will introduce the latest in the convergence of AI and HPC.
Featured speakers include:
- Jean-Marc Denis, Chief Strategy Officer of SiPearl, will describe new paradigms and challenges in Exascale era with the perspective of the key decisions made for Rhea processor architecture and design. Rhea is built on Arm's Neoverse V1 processor architecture, but it also has 29 RISC-V cores deployed as controllers. Rhea is planned to be deployed in an European Exascale supercomputer in 2023.
- Radoslav Danilak, CEO of Tachyum, will provide an overview of the features and benefits of Tachyum Prodigy, the world’s first Universal Processor. With 128 64-bit CPU cores operating at up to 5.7GHz, Prodigy not only handles general-purpose computing, HPC, and AI workloads on a single chip, it does so with a power budget that's 10 times lower than that of traditional hardware and at one-third the cost.
- Wolfgang Gentzsch, President of UberCloud, will summarize UberCloud’s 10 year achievements and present several customer use cases, and elaborate on UberCloud’s fully automated, portable, self-service, and multi-cloud engineering platform.
- Shu Yin, Assistant Professor at ShanghaiTech University, will share how to optimize HPC applications from the perspective of I/O, and will demonstrate best practices and use cases.
- Weizheng Lu, Tech Lead of Public Computing Center at Renmin University of China, will talk about Jax-Quant-Finance, and the High Performance Quantitative Library which brings HPC, Deep Learning, and Financial Mathematics together to accelerate financial problems time-to-resolution on heterogeneous platforms.
- Longxiang Li, Senior HPC engineer at Inspur Information, will detail the building of data-driven scientific workflows by coupling HPC with machine learning methods and introduce Inspur’s recent achievements in the fields of materials science, CFD, and ocean modeling.
The 29th HPC Connection Workshop Digital 2pm (CEST) May 30, 2022 Online |
Agenda |
Rhea Processor: Overall Strategic Directions and Specifications Jean-Marc Denis Chief Strategy Officer (CSO), SiPearl |
Tachyum Prodigy, The World’s First Universal Processor Radoslav Danilak CEO, Tachyum |
10 Year HPC in the Cloud: From Early Cloud Experiments to a Fully Automated Simulation Multi-Cloud Platform for Complex Engineering Workflows Wolfgang Gentzsch President of UberCloud |
Optimize HPC applications from the I/O perspectives Shu Yin Assistant Professor, ShanghaiTech University |
Jax-Quant-Finance: Bring HPC, Deep Learning and Financials Mathematics together Weizheng Lu Tech Lead of Public Computing Center, Renmin University of China |
Building data-driven scientific workflows with machine learning and HPC applications Longxiang Li Senior HPC engineer, Inspur Information |
Click here to register: http://www.asc-events.net/HPCC/ISC22.php
About HPC Connection Workshop
The HPC Connection Workshop is an international High Performance Computing event organized by the Asia Supercomputer Community and Inspur Information. This event takes place three times a year: during ASC in China, ISC in Germany, and SC in the USA. Top researchers and leading professionals from around the world gather at the workshops to discuss the latest developments and disruptive technologies in AI and supercomputing. Visit ASC's website for highlights and videos of the past events: (http://www.asc-events.org/ ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom